Amylyx Pharmaceuticals Inc (AMLX)
2.025
+0.02
(+1.25%)
USD |
NASDAQ |
May 03, 15:08
Amylyx Pharmaceuticals Total Liabilities (Quarterly): 84.02M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 84.02M |
| September 30, 2023 | 48.18M |
| June 30, 2023 | 67.22M |
| March 31, 2023 | 55.31M |
| December 31, 2022 | 50.85M |
| September 30, 2022 | 37.42M |
| Date | Value |
|---|---|
| June 30, 2022 | 32.45M |
| March 31, 2022 | 33.49M |
| December 31, 2021 | 256.78M |
| September 30, 2021 | 254.53M |
| December 31, 2020 | 80.83M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
32.45M
Minimum
Jun 2022
256.78M
Maximum
Dec 2021
91.01M
Average
55.31M
Median
Mar 2023
Total Liabilities (Quarterly) Benchmarks
| Cassava Sciences Inc | 14.20M |
| iRhythm Technologies Inc | 223.05M |
| Bristol-Myers Squibb Co | 82.48B |
| Moderna Inc | 4.572B |
| ACADIA Pharmaceuticals Inc | 317.20M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 517.45M |
| Shareholders Equity (Quarterly) | 433.43M |
| Current Ratio | 5.664 |